Physician

Amy Lucas Nance, M.D.

According to 2025 Medicare claims, Amy Nance, M.D. (NPI: 1407032097) practices hematology/oncology in the Gainesville, FL market, with the plurality of this provider's patient population coming from Alachua, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32605-4308. Nance is affiliated with the Gulf Coast Health Partners (ACO ID: A2299), participating under the MSSP model.

Nance's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,000 traditional Medicare patients, billed 294,158 HCPCS/CPT codes, and received $3,389,662 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,164 prescription claims across 248 beneficiaries totaling $2,077,032 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 30 claims. Open Payments data shows 33 records totaling $770. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,445,432 to $3,389,662. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,094,951 and ending at $2,077,032. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,376 to $5,234.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	883	99,261	$1,445,432
2016	743	73,465	$1,291,183
2017	628	49,218	$746,544
2018	422	60,365	$467,649
2019	598	154,601	$1,529,666
2020	608	201,420	$2,044,303
2021	603	205,979	$2,283,456
2022	736	274,531	$2,205,073
2023	735	224,867	$2,316,779
2024	1,000	294,158	$3,389,662

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	204	1,616	$1,094,951
2016	191	1,278	$1,172,600
2017	210	1,034	$706,032
2018	144	543	$264,233
2019	159	567	$275,281
2020	165	950	$932,207
2021	198	1,158	$1,734,600
2022	203	1,165	$1,432,467
2023	201	951	$1,462,338
2024	248	1,164	$2,077,032

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	57	$20,429
2016	N/R	68	$21,888
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	37	$3,249
2021	N/R	44	$3,278
2022	N/R	45	$10,275
2023	N/R	N/R	N/R
2024	N/R	30	$743

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	365	706	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	287	440	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	196	267	$13
36415	Insertion of needle into vein for collection of blood sample	725	2,139	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	699	2,166	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	26	780	$395,710
Revlimid	Lenalidomide	26	637	$390,057
Ibrance	Palbociclib	16	448	$247,368
Imbruvica	Ibrutinib	13	364	$212,751
Erleada	Apalutamide	14	420	$203,906

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$404
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$770	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amy Lucas Nance, M.D.?

Tedicare shows public-source Medicare data for Amy Lucas Nance, M.D. (NPI 1407032097), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amy Lucas Nance, M.D. have ACO affiliation data?

Amy Lucas Nance, M.D. is shown with ACO affiliation data for Gulf Coast Health Partners (MSSP, ACO ID A2299).

What billing organization is linked to Amy Lucas Nance, M.D.?

Amy Lucas Nance, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Amy Lucas Nance, M.D. have Open Payments data?

Amy Lucas Nance, M.D. has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.